Abstract
In clinical practice, we have many products intervening on the level of blood vessel formation. It the so-called anti-angiogenic drugs.
In this article, we deal with drugs targeted against the blood vessels, vascular disrupting drugs (EAD). The aim of these drugs is to make rapid destruction of existing blood vessels, causing a sharp drop in tumor perfusion and thus induce tumor necrosis.
While many antiangiogenic drug delivery has undergone clinical phase III study, and are routinely used drugs before the second group are at the very beginning of clinical trials and only one of them advanced to the second phase of tests.